Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sulfoximines as potent RORγ inverse agonists.
Ouvry G, Bihl F, Bouix-Peter C, Christin O, Defoin-Platel C, Deret S, Feret C, Froude D, Hacini-Rachinel F, Harris CS, Hervouet C, Lafitte G, Luzy AP, Musicki B, Orfila D, Parnet V, Pascau C, Pascau J, Pierre R, Raffin C, Rossio P, Spiesse D, Taquet N, Thoreau E, Vatinel R, Vial E, Hennequin LF. Ouvry G, et al. Among authors: lafitte g. Bioorg Med Chem Lett. 2018 May 1;28(8):1269-1273. doi: 10.1016/j.bmcl.2018.03.041. Epub 2018 Mar 17. Bioorg Med Chem Lett. 2018. PMID: 29571573
Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis.
Ouvry G, Atrux-Tallau N, Bihl F, Bondu A, Bouix-Peter C, Carlavan I, Christin O, Cuadrado MJ, Defoin-Platel C, Deret S, Duvert D, Feret C, Forissier M, Fournier JF, Froude D, Hacini-Rachinel F, Harris CS, Hervouet C, Huguet H, Lafitte G, Luzy AP, Musicki B, Orfila D, Ozello B, Pascau C, Pascau J, Parnet V, Peluchon G, Pierre R, Piwnica D, Raffin C, Rossio P, Spiesse D, Taquet N, Thoreau E, Vatinel R, Vial E, Hennequin LF. Ouvry G, et al. Among authors: lafitte g. ChemMedChem. 2018 Feb 20;13(4):321-337. doi: 10.1002/cmdc.201700758. Epub 2018 Feb 6. ChemMedChem. 2018. PMID: 29327456
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
Fournier JF, Bhurruth-Alcor Y, Musicki B, Aubert J, Aurelly M, Bouix-Peter C, Bouquet K, Chantalat L, Delorme M, Drean B, Duvert G, Fleury-Bregeot N, Gauthier B, Grisendi K, Harris CS, Hennequin LF, Isabet T, Joly F, Lafitte G, Millois C, Morgentin R, Pascau J, Piwnica D, Rival Y, Soulet C, Thoreau É, Tomas L. Fournier JF, et al. Among authors: lafitte g. Bioorg Med Chem Lett. 2018 Sep 15;28(17):2985-2992. doi: 10.1016/j.bmcl.2018.06.029. Epub 2018 Jun 18. Bioorg Med Chem Lett. 2018. PMID: 30122227
13 results